Liquidia Co. (NASDAQ:LQDA) General Counsel Sells $193,109.54 in Stock

Liquidia Co. (NASDAQ:LQDA) General Counsel Russell Schundler sold 16,393 shares of the company’s stock in a transaction dated Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total value of $193,109.54. Following the sale, the general counsel now owns 573,478 shares in the company, valued at approximately $6,755,570.84. This represents a 2.78 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Russell Schundler also recently made the following trade(s):

• On Monday, December 2nd, Russell Schundler sold 1,063 shares of Liquidia stock. The shares were sold at an average price of $11.51, for a total transaction of $12,235.13.

Liquidia Stock Performance

Shares of LQDA opened at $12.51 on Friday. Liquidia Co. has a fifty-two week low of $8.26 and a fifty-two week high of $16.99. The firm has a market cap of $1.06 billion, a price-to-earnings ratio of -7.67 and a beta of 0.23. The firm has a 50 day moving average price of $11.26 and a 200-day moving average price of $11.03.

Institutional Trading of Liquidia

Several hedge funds have recently added to or reduced their stakes in LQDA. Bank of New York Mellon Corp increased its holdings in shares of Liquidia by 18.2% in the second quarter. Bank of New York Mellon Corp now owns 207,961 shares of the company’s stock worth $2,496,000 after buying an additional 32,076 shares during the period. Rhumbline Advisers grew its position in Liquidia by 12.4% during the 2nd quarter. Rhumbline Advisers now owns 80,164 shares of the company’s stock worth $962,000 after acquiring an additional 8,871 shares during the last quarter. Arizona State Retirement System increased its stake in Liquidia by 10.7% in the 2nd quarter. Arizona State Retirement System now owns 13,842 shares of the company’s stock worth $166,000 after purchasing an additional 1,341 shares during the period. Quest Partners LLC bought a new stake in Liquidia in the second quarter valued at approximately $27,000. Finally, Profund Advisors LLC boosted its stake in shares of Liquidia by 31.6% during the second quarter. Profund Advisors LLC now owns 14,434 shares of the company’s stock valued at $173,000 after purchasing an additional 3,466 shares during the period. 64.54% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

LQDA has been the subject of several analyst reports. Lifesci Capital started coverage on shares of Liquidia in a report on Thursday, October 3rd. They issued an “outperform” rating and a $30.00 price target for the company. Wells Fargo & Company initiated coverage on Liquidia in a research report on Friday, December 20th. They set an “overweight” rating and a $20.00 target price for the company. Scotiabank initiated coverage on Liquidia in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $30.00 price target on the stock. HC Wainwright reiterated a “buy” rating and set a $29.00 price target on shares of Liquidia in a research report on Thursday, November 14th. Finally, Needham & Company LLC restated a “buy” rating and issued a $19.00 price objective on shares of Liquidia in a research report on Thursday, January 9th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $25.38.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).